<DOC>
	<DOCNO>NCT03067350</DOCNO>
	<brief_summary>Hypothesis : A pharmacogenetic score integrate CYP3A genotype could influence initial trough voriconazole plasma concentration thus useful adapt priori voriconazole dose order get adequate voriconazole exposure possible start treatment . Main Objective : To determine predictive value combine pharmacogenetic score onset trough voriconazole plasma concentration inferior low therapeutic target .</brief_summary>
	<brief_title>Influence Combined Pharmacogenetic Score Through Plasma Voriconazole Concentrations Haematological Patients</brief_title>
	<detailed_description>Voriconazole ( VRC ) , gold-standard treatment invasive aspergillosis characterize variable nonlinear pharmacokinetics , cause many under- over-dosing . A link exist trough plasma concentration ( Cmin ) VRC effectiveness also toxicity . Thus longitudinal therapeutic drug monitoring VRC recommend therapeutic range 1 5 mg/L . The pharmacokinetic variability VRC part explain metabolism , mainly dependent cytochrome P 450 ( CYP ) , particularly CYP2C19 , 3A4 , 3A5 ; CYP exhibit genetic polymorphism . The author , recently show , first time , retrospective study conduct 29 patient allogeneic hematopoietic stem cell initial VRC Cmin adjust dose influence route administration also pharmacogenetics score whose determination assign genotype CYP2C19 CYP3A score express arbitrary unit . The combined pharmacogenetic score strongly correlate original Cmin ( r= -0.748 ; p = 0.002 ) independent predictor initial Cmin ( adjust dose route administration ) . In addition , none patient genetic score &lt; 2 ( ie metabolizing capacity reduce VRC ) show initial Cmin 1 mg/L , initial Cmin threshold efficiency 47 % patient genetic score &gt; 2 . The aim new study confirm impact pharmacogenetic score initial VRC Cmin large prospective cohort 60 adult patient onco-hematological disease .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>patient suffer haematological cancer le 18years old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>voriconazole</keyword>
	<keyword>pharmacogenetics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>therapeutic drug monitoring</keyword>
</DOC>